These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 36813538)
1. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Glintborg B; Di Giuseppe D; Wallman JK; Nordström DC; Gudbjornsson B; Hetland ML; Askling J; Grondal G; Sokka T; Provan SA; Michelsen B; Kristianslund EK; Dreyer L; Love TJ; Lindström U Ann Rheum Dis; 2023 Jun; 82(6):820-828. PubMed ID: 36813538 [TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs. Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751 [No Abstract] [Full Text] [Related]
3. Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis. Gossec L; Humphries B; Rutherford M; Taieb V; Willems D; Tillett W Arthritis Res Ther; 2024 Feb; 26(1):50. PubMed ID: 38360699 [TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Kawalec P; Holko P; Moćko P; Pilc A Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605 [TBL] [Abstract][Full Text] [Related]
5. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia. Fletcher A; Lassere M; March L; Hill C; Barrett C; Carroll G; Buchbinder R Rheumatology (Oxford); 2022 Oct; 61(10):3939-3951. PubMed ID: 35094044 [TBL] [Abstract][Full Text] [Related]
6. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Michelsen B; Georgiadis S; Di Giuseppe D; Loft AG; Nissen MJ; Iannone F; Pombo-Suarez M; Mann H; Rotar Z; Eklund KK; Kvien TK; Santos MJ; Gudbjornsson B; Codreanu C; Yilmaz S; Wallman JK; Brahe CH; Möller B; Favalli EG; Sánchez-Piedra C; Nekvindova L; Tomsic M; Trokovic N; Kristianslund EK; Santos H; Löve TJ; Ionescu R; Pehlivan Y; Jones GT; van der Horst-Bruinsma I; Ørnbjerg LM; Østergaard M; Hetland ML Arthritis Care Res (Hoboken); 2022 Jul; 74(7):1205-1218. PubMed ID: 33460531 [TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis. Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807 [TBL] [Abstract][Full Text] [Related]
8. Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis. Lee BW; Lee JJ; Kim WU Korean J Intern Med; 2024 Sep; 39(5):833-844. PubMed ID: 38798047 [TBL] [Abstract][Full Text] [Related]
9. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs. Baker MC; Liu Y; Lu R; Lin J; Melehani J; Robinson WH JAMA Netw Open; 2023 Mar; 6(3):e233640. PubMed ID: 36939701 [TBL] [Abstract][Full Text] [Related]
10. One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses. Glintborg B; Lindström U; Giuseppe DD; Provan SA; Gudbjornsson B; Hetland ML; Michelsen B; Wallman JK; Aaltonen K; Hokkanen AM; Nordström D; Jørgensen TS; Hansen RL; Geirsson AJ; Grøn KL; Krogh NS; Askling J; Kristensen LE; Jacobsson LTH; Arthritis Care Res (Hoboken); 2022 May; 74(5):748-758. PubMed ID: 33253491 [TBL] [Abstract][Full Text] [Related]
11. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis. Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. Ruyssen-Witrand A; Perry R; Watkins C; Braileanu G; Kumar G; Kiri S; Nott D; Liu-Leage S; Hartz S; Sapin C RMD Open; 2020 Feb; 6(1):. PubMed ID: 32094304 [TBL] [Abstract][Full Text] [Related]
14. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study. Wu N; Lee YC; Shah N; Harrison DJ Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652 [TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038 [TBL] [Abstract][Full Text] [Related]
16. Treatment persistence of biologics among patients with psoriatic arthritis. Haddad A; Gazitt T; Feldhamer I; Feld J; Cohen AD; Lavi I; Tatour F; Bergman I; Zisman D Arthritis Res Ther; 2021 Jan; 23(1):44. PubMed ID: 33514410 [TBL] [Abstract][Full Text] [Related]
17. No difference in clinical parameters and drug retention in PsA patients receiving b/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry. Regierer AC; Kiefer D; Schett G; Krause A; Weiß A; Sewerin P; Strangfeld A RMD Open; 2024 Jul; 10(3):. PubMed ID: 39043613 [TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis. Zhang H; Wen J; Alexander GC; Curtis JR RMD Open; 2021 Apr; 7(1):. PubMed ID: 33863840 [TBL] [Abstract][Full Text] [Related]
19. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Chiu YM; Chen DY Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268 [No Abstract] [Full Text] [Related]
20. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis. Ungprasert P; Thongprayoon C; Davis JM Clin Rheumatol; 2016 Jul; 35(7):1795-803. PubMed ID: 26852316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]